TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10428124
Drug: Enoxaparin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (30 mg every 12 hours)
Study: 7555502
Drug: Diet alone
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet alone (normal daily routine, 4,500 +/- 290 steps/day)
Study: 6158861
Drug: Control (routine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (routine treatment with sedatives, bed rest, and magnesium sulfate)
Study: 27593801
Drug: Conservative therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative therapy (Control)
Study: 21864907
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) formulation, 600 mg single dose
Study: 21864907
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation, 300 mg single dose
Study: 21864907
Drug: Controlled-release (CR)
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled-release (CR) formulation, 600 mg q12h multiple doses
Study: 21864907
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) formulation, 300 mg q6h multiple doses
Study: 19702486
Drug: Atomoxetine 1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine 1.8 mg/kg per day
Study: 19702486
Drug: Atomoxetine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (0.5 mg/kg per day, 1.2 mg/kg per day, 1.8 mg/kg per day)
Study: 15627870
Drug: Inhaled formoterol
Normalized name: formoterol Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled formoterol (9 microg) twice a day
Study: 15627870
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast (10 microg) once a day
Study: 9412655
Drug: Cyclophosphamide 100
Normalized name: cyclophosphamide 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 100 mg/m2, Methotrexate 40 mg/m2, 5-Fluorouracil 600 mg/m2 (CMF)
Study: 9412655
Drug: Epidoxorubicin 75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidoxorubicin 75 mg/m2 and Vincristine 0.75 mg/m2 (EV)
Study: 9412655
Drug: Mitomycin-C 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitomycin-C 10 mg/m2 and Vindesine 2 mg/m2 (MVs)
Study: 8276739
Drug: Clomipramine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine at top doses of 150 mg/day for 3 weeks
Study: 28780551
Drug: Indigenous Counselling
Normalized name: Indigenous peanut oil
DrugBank: Peanut oil (DB13964)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indigenous Counselling And Nicotine (ICAN) QUIT in Pregnancy intervention including webinar training, educational resources, free oral nicotine replacement therapy (NRT), and audit and feedback.
Study: 26121878
Drug: Tiotropium 18
Normalized name: TIOTROPIUM 18MCG CAP,INHL,6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium 18 µg Qd
Study: 26121878
Drug: Ipratropium 40
Normalized name: Ipratropium
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium 40 µg Qid
Study: 25422827
Drug: Way Milano
Approvals — FDA: no, EMA: no, PMDA: no
Description: Way Milano implants
Study: 25422827
Drug: Kentron implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kentron implants
Study: 12074370
Drug: Pharmacotherapy (PCT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy (PCT)
Study: 18358928
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with FOLFOX4 (6 cycles before and 6 cycles after surgery)
Study: 18358928
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy with FOLFOX4
Study: 15737450
Drug: Step lengthening
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step lengthening (twice a day)
Study: 12534148
Drug: EGFR inhibitory
Normalized name: Egfr t790m inhibitor pf-06747775
DrugBank: Mavelertinib (DB16228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR inhibitory agents
Study: 7863991
Drug: Antiarrhythmic drug
Normalized name: ANTIARRHYTHMICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiarrhythmic drug therapy (amiodarone and sotalol)
Study: 30325777
Drug: Antiretroviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiretroviral treatment interruption (ATI)
Study: 27907921
Drug: DCF (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCF (docetaxel 70 mg/m2, cisplatin 70 mg/m2 on day 1, and 5‐fluorouracil 700 mg/m2 for 5 days) every 3 weeks
Study: 27907921
Drug: ACF (adriamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACF (adriamycin 35 mg/m2, cisplatin 70 mg/m2 on day 1, and 5‐FU 700 mg/m2 for 7 days) every 4 weeks
Study: 23114369
Drug: bivalent rLP2086
Normalized name: L1 protein, human papillomavirus type 16 vaccine
DrugBank: Human papillomavirus type 16 L1 capsid protein antigen (DB10301)
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalent rLP2086 vaccine (20 µg, 60 µg, 200 µg)
Study: 21861128
Drug: Thalidomide 400
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Thalidomide 400 mg orally daily
Study: 21861128
Drug: Irinotecan 350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 350 mg/m2 intravenously every 3 weeks
Study: 17004124
Drug: High-dose pegylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose pegylated interferon alpha-2b plus ribavirin
Study: 17004124
Drug: Low-dose pegylated
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose pegylated interferon alpha-2b plus ribavirin
Study: 15266728
Drug: Pharmaceutical company
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmaceutical company advertisements
Study: 15266728
Drug: Scientific information
Normalized name: Inflammation OTC Bruise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scientific information about depression and its treatment
Study: 9212966
Drug: Heparin-bonded partial
Normalized name: SOY OIL,PARTIALLY HYDROGENATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded partial cardiopulmonary bypass with nafamostat mesilate
Study: 8428872
Drug: Desipramine (DMI)
DrugBank: Desipramine (DB01151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Desipramine (DMI) at daily doses averaging 4 to 5 mg/kg
Study: 24948414
Drug: 5% NaHCO3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% NaHCO3 solution at 45‐50°C
Study: 11004053
Drug: Oral nifedipine
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral nifedipine (60 mg)
Study: 11004053
Drug: Intravenous nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nimodipine (30 microg x kg(‐1) x h(‐1) over 20 h)
Study: 11004053
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (initial dose of 30 mg/kg followed by 10 mg x kg(‐1) x h(‐1) over 20 h)
Study: 1754849
Drug: Nocloprost 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocloprost 100 micrograms three times daily
Study: 31935118
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids (4 capsules, 2.4 g daily for 12 weeks)
Study: 23994918
Drug: Cytoflavin (20‐40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (20‐40 ml daily intravenously in drops for 10 days)
Study: 22290679
Drug: Dexketoprofen 25
Normalized name: dexketoprofen 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexketoprofen 25 mg (Group D)
Study: 22290679
Drug: Paracetamol 500
Normalized name: Paracetamol 500 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 500 mg (Group P)
Study: 19803237
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of Probenecid (on the basis of diet intervention)
Study: 16891570
Drug: Paroxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine treatment for 12 months
Study: 16012271
Drug: Ziprasidone (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ziprasidone (40 to 80 mg BID)
Study: 9856370
Drug: Lisinopril at
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril at 20 mg with the addition of 12.5 or 25 mg hydrochlorothiazide as needed
Study: 2797545
Drug: Fluoride rinse
Normalized name: ACT Fluoride Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride rinse (0.2 percent sodium fluoride solution)
Study: 344898
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cyclophosphamide, methotrexate, 5‐fluorouracil, vincristine, and prednisone (repeated weekly treatment)
Study: 344898
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment of the same five drugs given in 5‐day courses every 4 weeks
Study: 344898
Drug: Adriamycin as
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin as a single agent (treatment every 3 weeks)
Study: 3890229
Drug: Treatment effect
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effect
Study: 28504067
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercise plus TrP dry needling (DN)
Study: 28504067
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy and exercises
Study: 23776118
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa (Darbe) 10 μg/kg, 1 time per week subcutaneously
Study: 23776118
Drug: Placebo (sham
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sham dosing)
Study: 19036233
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day of quetiapine fumarate
Study: 19036233
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day of quetiapine fumarate
Study: 19036233
Drug: Flexible dosing
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible dosing in Part 2
Study: 10534145
Drug: Didanosine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Didanosine and stavudine (100 + 10 mg, 100 + 20 mg, 100 + 40 mg, 200 + 20 mg, and 200 + 40 mg)
Study: 10534145
Drug: High-dose subgroup
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose subgroup (arms 3, 4, and 5)
Study: 10534145
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (didanosine and stavudine)
Study: 1817622
Drug: Verapamil 0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil 0.01 mg kg‐1 h‐1 (n = 12)
Study: 6983207
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin D2 (450 IU) with 420 mg calcium daily
Study: 6983207
Drug: Calcium alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium alone (420 mg)
Study: 30597503
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of 40 mg daily LMWH
Study: 26445532
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Polygonum minus extract (PM) taken twice daily for 6 weeks
Study: 22425113
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with sham escalation
Study: 19092364
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy (granulocyte colony-stimulating factor, erythropoietin, and stem cell factor)
Study: 20364382
Drug: Cytokine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine therapy alone
Study: 19092364
Drug: Various combinations
Normalized name: various combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various combinations of cytokines with or without stem cell therapy
Study: 17297068
Drug: Training +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training + Medication (TM)
Study: 17297068
Drug: Training +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training + Incentive + Medication (TI+TM)
Study: 9058557
Drug: Supportive-expressive (SE)
Normalized name: Selenomethionine Se-75
DrugBank: Selenomethionine Se-75 (DB09400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive-expressive (SE) therapy
Study: 11302268
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling (IDC)
Study: 3731684
Drug: prazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: prazosin (1 mg t.i.d.)
Study: 26999688
Drug: Antioxidants (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (1 gram L-ascorbic acid per day)
Study: 22921557
Drug: Home-based cyclergometer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based cyclergometer training (30 min/day for 3 months, with monthly-supervised sessions)
Study: 7865644
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin 300 mg
Study: 7865644
Drug: Plain aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain aspirin 75 mg
Study: 10102949
Drug: Enteric-coated aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enteric-coated aspirin 300 mg
Study: 7432659
Drug: Alpha-mercaptopropionylglycine (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-mercaptopropionylglycine (1500 mg/day per os)
Study: 27234460
Drug: Low polyunsaturated
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low polyunsaturated fat intake (1-4 g)
Study: 27234460
Drug: High polyunsaturated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyunsaturated fat intake (6-12 g)
Study: 24794282
Drug: Verteporfin photodynamic
Normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Verteporfin photodynamic therapy (PDT) combination therapy
Study: 12419644
Drug: New formulation
Normalized name: TRIPROLIDINE HYDROCHLORIDE 1.25 mg in 1 mL ORAL SYRUP [HISTEX PD Drops New Formulation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: New formulation of ticlopidine hydrochloride (250mg)
Study: 12419644
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation Tiklid (250mg)
Study: 7621491
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 10 to 80 mg urea per piece, chewed for 10 minutes.
Study: 7621491
Drug: Two pieces
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two pieces of gum containing 20 mg urea each, chewed for 10 minutes.
Study: 7621491
Drug: Three pieces
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three pieces of gum containing 20 mg urea each, chewed one after the other (10 + 10 + 10 min).
Study: 7226953
Drug: Inhaled distilled
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled distilled water plus intramuscular (IM) saline solution
Study: 7226953
Drug: Inhaled A
Normalized name: Inhaled allergen mix specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled A dose of atropine plus IM saline solution
Study: 7226953
Drug: Inhaled distilled
Normalized name: petroleum distillate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled distilled water plus 0.35 mg IM atropine
Study: 7226953
Drug: Inhaled A
Normalized name: Inhaled allergen mix specific IgE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled A dose of atropine plus 0.35 mg IM atropine
Study: 7226953
Drug: Inhaled double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled double the A dose plus IM saline solution
Study: 29334921
Drug: Brief Social
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief Social Behaviour and Network Therapy (B‐SBNT) + Treatment as Usual (TAU)
Study: 29334921
Drug: Personal Goal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal Goal Setting (PGS) + Treatment as Usual (TAU)
Study: 27189286
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (1000 IU during screening, median doses of 2000 IU daily)
Study: 24219351
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy for psychosis
Study: 17033909
Drug: Doxorubicin‐cisplatin (AP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin‐cisplatin (AP) chemotherapy
Study: 15702045
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose azithromycin (30 mg/kg)
Study: 15702045
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose amoxicillin (90 mg/kg/d, in 2 divided doses for 10 days)
Study: 21815708
Drug: Pravastatin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10-20 mg/day)
Study: 11999665
Drug: Conventional lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lipid-lowering drugs (fibrates, nicotinic acid, probucol)
Study: 10458219
Drug: MA 160
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 160 mg/d (one tablet per day)
Study: 10458219
Drug: MA 800
Normalized name: Zhi ma oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 800 mg/d (five tablets per day)
Study: 10458219
Drug: MA 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: MA 1,600 mg/d (10 tablets per day)
Study: 350254
Drug: Various existing
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various existing methods of allocation to treatment groups
Study: 27473843
Drug: Simvastatin 40
Normalized name: simvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 40 mg for 12 months
Study: 18585908
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Study: 18585908
Drug: Supralingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supralingual immunotherapy with standardized allergen extract (H‐Al per os) for one year.
Study: 18585908
Drug: Sublingual active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual active group
Study: 16988729
Drug: Continuous renal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous renal replacement therapy (CRRT) at a dose of 35-45 ml/kg/h
Study: 11032586
Drug: Tamoxifen (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (20 to 30 mg/d for >/= 2 years)
Study: 8252955
Drug: Oxitropium bromide
Normalized name: oxitropium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxitropium bromide (0.2 mg)
Study: 8252955
Drug: Combined oxitropium
Normalized name: oxitropium
DrugBank: Oxitropium (DB12086)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oxitropium and fenoterol (0.2 mg and 0.4 mg)
Study: 28641369
Drug: Soluble intercellular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble intercellular adhesion molecule‐1 (quintile 5 vs. quintile 1)
Study: 15602800
Drug: Fluindione 20
Normalized name: fluindione 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluindione 20 mg
Study: 1848268
Drug: Itraconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole (200 mg orally twice daily)
Study: 1848268
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (0.6 mg/kg daily or 0.3 mg/kg in combination with flucytosine)
Study: 6676676
Drug: Carbamazepine 100
Normalized name: carbamazepine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 100 mg/day for 8 days
Study: 25083241
Drug: Night-time dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night-time dosing of thiazide diuretics
Study: 25083241
Drug: Morning dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning dosing of thiazide diuretics
Study: 11873000
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Pravastatin 40 mg daily (arm 1)
Study: 11873000
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Simvastatin 40 mg daily (arm 2)
Study: 11873000
Drug: Ritonavir (RTV)
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir (RTV) 400 mg and Saquinavir soft-gel (SQVsgc) 400 mg twice daily with Atorvastatin 40 mg daily (arm 3)
Study: 11873000
Drug: Nelfinavir (NFV)
DrugBank: Nelfinavir (DB00220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nelfinavir (NFV) 1250 mg twice daily with Pravastatin 40 mg daily (arm 4)
Study: 31254522
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 mL saline)
Study: 25631970
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of ferrous sulfate twice a week for 16 weeks
Study: 19782353
Drug: Single preovulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preovulatory intrauterine insemination (IUI) performed 24 hours after hCG administration
Study: 19782353
Drug: Two IUIs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two IUIs performed 12 and 36 hours after hCG administration
Study: 19782353
Drug: Single periovulatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single periovulatory IUI performed 36 hours after hCG administration